Best Time to Take Iron
Read More
Cagrilintide Dosage With Semaglutide
Key Takeaways
CagriSema targets two separate appetite pathways simultaneously, which is why trial results exceed either drug used alone.
The maintenance dose is a fixed 2.4mg cagrilintide plus 2.4mg semaglutide, reached through a structured multi-step escalation over roughly 16 weeks.
REDEFINE 1 clinical trial data showed approximately 22 percent average body weight reduction at 68 weeks, setting a new benchmark above current approved options.
CagriSema is still investigational and is not available by prescription outside of supervised clinical trials as of early 2025.
Patients already on semaglutide should never attempt to self-combine cagrilintide; the combination requires a medically supervised dosing protocol.
What Cagrilintide Is and Why It Pairs With Semaglutide
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It mimics amylin, a pancreatic hormone that helps suppress appetite and slows the rate at which the stomach empties after a meal. Semaglutide, sold under brand names like Ozempic for type 2 diabetes and Wegovy for obesity, is a GLP-1 receptor agonist with well-established dosing protocols and a strong track record in clinical use.
The rationale for combining these two compounds is straightforward. Each one works on a distinct satiety pathway. GLP-1 receptor agonists reduce appetite primarily through central and peripheral signaling tied to the incretin system, while amylin analogues act through different receptors in the brain and gut. Hitting both pathways at once may produce greater appetite suppression and weight loss than either agent achieves alone. This mechanistic logic led to the development of a fixed-ratio co-formulation called CagriSema, which delivers both drugs in a single weekly injection.
How Dosing Is Structured in CagriSema Trials
The REDEFINE clinical trial program, which is the primary evidence base for CagriSema, uses a fixed maintenance dose of cagrilintide 2.4mg combined with semaglutide 2.4mg, administered as a single subcutaneous injection once per week. This is not the starting dose. Like semaglutide monotherapy, CagriSema follows a careful escalation schedule to give the body time to adjust and to minimize gastrointestinal side effects such as nausea and vomiting.
The escalation spans approximately 16 weeks. Both components are increased in parallel steps, meaning patients are not at a full semaglutide dose or a full cagrilintide dose until the final escalation step is complete. The injection route and weekly schedule remain the same throughout, which supports familiarity and adherence for patients already experienced with semaglutide.
The Escalation Schedule Step by Step
The dose escalation begins conservatively and mirrors the ramp-up that semaglutide monotherapy uses. Starting at 0.25mg of cagrilintide plus 0.25mg of semaglutide, patients increase the combined dose approximately every four weeks. Intermediate steps move through 0.5mg/0.5mg, then 1.0mg/1.0mg, then 1.7mg/1.7mg, before arriving at the full maintenance dose of 2.4mg/2.4mg.
This graduated approach reflects lessons learned from GLP-1 agonist development, where too-rapid dose increases frequently lead to gastrointestinal intolerance and early discontinuation. Because nausea and vomiting are among the most common side effects for both drug classes, the parallel escalation strategy is designed to keep tolerability manageable at every stage without extending the overall time to reach full therapeutic dose.
What Clinical Trial Data Shows About Efficacy
Results from the REDEFINE 1 trial offer the most detailed picture of what CagriSema may achieve at the 2.4mg/2.4mg maintenance dose. Participants experienced a mean body weight reduction of approximately 22 percent at 68 weeks. A meaningful subset surpassed 25 percent weight loss, which is a threshold rarely reached with any single currently approved agent. Secondary outcomes including waist circumference, fasting blood glucose, blood pressure, and lipid profiles also showed improvements, consistent with the dual mechanism addressing both metabolic and appetite-related pathways.
The table below compares CagriSema with two currently approved options to place the trial data in context.
Therapy |
Mechanism |
Maintenance Dose |
Escalation Duration |
Approx. Weight Loss in Trials |
Approval Status |
|---|---|---|---|---|---|
CagriSema |
GLP-1 agonist plus amylin analogue |
2.4mg/2.4mg weekly |
~16 weeks |
~22% body weight |
Investigational (as of early 2025) |
Semaglutide 2.4mg (Wegovy) |
GLP-1 receptor agonist |
2.4mg weekly |
~16 weeks |
~15% body weight |
FDA approved for obesity |
Tirzepatide 15mg (Zepbound) |
GLP-1 and GIP dual agonist |
15mg weekly |
~20 weeks |
~20-21% body weight |
FDA approved for obesity |
These figures come from separate trial populations with different designs, so direct comparisons should be interpreted carefully. What the data suggests is that CagriSema may represent a step forward even relative to the most effective currently approved options.
How CagriSema Compares With Semaglutide Monotherapy Dosing
For patients already familiar with Wegovy, one practical question is how different the CagriSema experience would feel. The answer, based on trial design, is that the two are closely matched in structure. Both reach their maintenance doses after a 16-week escalation starting at 0.25mg. Both use subcutaneous injection once weekly. The total injection volume and administration site remain comparable, which matters for patients who have already developed a routine around semaglutide.
The key difference is the addition of the cagrilintide component at every escalation step, which means both drugs are ramping up simultaneously rather than one being added to a stable background therapy. This parallel structure means there is no separate titration period or adjustment phase for each drug independently. Patients move through one unified schedule.
Regulatory Status and What This Means for Patients Today
As of early 2025, CagriSema has not received FDA approval. It remains an investigational compound, meaning it is only accessible through clinical trials. Novo Nordisk has submitted data from the REDEFINE program to regulatory agencies, and a potential approval decision is anticipated sometime in 2025 or 2026, though timelines in drug development can shift.
For patients currently on semaglutide who are following the CagriSema pipeline with interest, there is an important caution. Cagrilintide is not available as a standalone prescription, and attempting to source or combine any unapproved compound with an existing semaglutide prescription outside of a supervised protocol is not safe. The dosing schedule in trials exists within a structured medical environment with regular monitoring, not as a self-directed regimen.
Doctronic has completed more than 22 million AI consultations, with 99.2% treatment plan alignment with board-certified physicians, and is available 24/7 to help patients understand their current approved treatment options while staying informed about what the pipeline may offer. Patients who want to evaluate whether they are on the most appropriate current therapy, or who have questions about eligibility for clinical trials, should speak with a licensed clinician before making any changes.
Frequently Asked Questions
The maintenance dose used in CagriSema clinical trials is 2.4mg of cagrilintide combined with 2.4mg of semaglutide, delivered as a single subcutaneous injection once weekly. This full dose is not the starting point. Patients work up to it through a gradual escalation schedule designed to reduce gastrointestinal side effects.
The escalation schedule spans approximately 16 weeks, with dose increases occurring roughly every four weeks. Steps move from 0.25mg/0.25mg up through 0.5mg, 1.0mg, and 1.7mg before reaching the full 2.4mg/2.4mg maintenance dose. This timeline mirrors the cautious ramp-up already used for semaglutide monotherapy.
No. Cagrilintide is not approved or available by prescription as of early 2025. Attempting to self-combine any experimental compound with a current semaglutide prescription outside of a supervised clinical protocol carries serious safety risks. Speak with a licensed clinician before making any changes to your current treatment plan.
REDEFINE 1 trial data showed a mean body weight reduction of approximately 22 percent at 68 weeks with the full CagriSema dose, outperforming semaglutide 2.4mg monotherapy. A notable subset of participants lost more than 25 percent of their body weight, a threshold rarely reached with any single approved agent.
Novo Nordisk has submitted REDEFINE program data to regulators, and a potential FDA approval decision is anticipated sometime in 2025 or 2026. Until approval is granted, CagriSema remains investigational and is only accessible through clinical trials. Approval timelines can shift, so consulting a healthcare provider for updates is recommended.
The Bottom Line
CagriSema represents a promising next step beyond semaglutide monotherapy, pairing a 2.4mg cagrilintide dose with a 2.4mg semaglutide dose through the same manageable 16-week escalation already familiar to many patients. Clinical trial results showing roughly 22 percent average weight loss signal a meaningful advance in obesity treatment. However, FDA approval is still pending, and the combination is not yet available outside of trials. Doctronic, the first AI legally authorized to practice medicine, offers free 24/7 consultations to help you evaluate your current options and prepare informed questions for your care team. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
